Background--Clinical trials traditionally use time-to-first-event analysis embedded within the composite endpoint of cardiovascular death (CVD), myocardial infarction (MI), or stroke. However, many patients have >1 event, and this approach may not reflect overall experience. We addressed this by analyzing all cardiovascular events in TRACER.
M ost clinical trials incorporate "time to first event" into their primary analyses and do not take into account the effect of therapy after the initial event. Therefore, the disease burden and effectiveness and safety of a therapy may not represent the totality of the patient experience. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial randomized nearly 13 000 patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) to the protease-activated receptor 1 antagonist vorapaxar or placebo. The study was terminated prematurely, after enrollment completion and the target endpoint was reached, following an unplanned, independent safety review of excess bleeding hazard. Randomization to vorapaxar was associated with no significant effect on the first occurrence of the primary composite endpoint of cardiovascular death (CVD), myocardial infarction (MI), stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization (hazard ratio [HR] , 0.92; 95% confidence interval [CI] , 0.85 to 1.01; P=0.07). There was, however, a nominal reduction of the prespecified, secondary, time-toevent composite endpoint of CVD, MI, or stroke (HR, 0.89; 95% CI, 0.81 to 0.98; P=0.02).
In the current report, we further explored the effect of randomized treatment with placebo or vorapaxar on overall event history of CVD, MI, or stroke. We also explored the effect of treatment on overall occurrences of bleeding events.
Methods
The TRACER trial's design, 3 endpoint definitions, and primary results have been reported. 2 In summary, this double-blind, placebo-controlled, event-driven, international trial in 37 countries compared placebo with vorapaxar (40-mg loading dose followed by 2.5 mg daily) in patients with NSTE ACS at high risk for ischemic events. Patients were planned to be followed for at least 1 year. All patients who experienced nonfatal events were recommended to continue the randomized treatment.
The TRACER study was approved by institutional review committees and all patients gave informed consent.
Statistical Analysis
We analyzed overall occurrences of the composite ischemic endpoints and composite bleeding endpoints as described above. As prespecified in the protocol, analyses of efficacy endpoints included all randomized subjects with events accrued from randomization to last follow-up. Analyses of bleeding endpoints included subjects with at least 1 dose of randomized treatment with events accrued while on treatment.
Baseline characteristics were presented for patients who experienced none, 1, or multiple composite endpoints. To investigate the effect of vorapaxar on occurrences of events, we employed the stratified Cox model proposed by Wei, Lin, and Weissfeld (the WLW model). 4 The WLW model allows us to consider the ordering of events as separate events (ie, strata) of interest, as well as the different types of events that may occur in the same patient (eg, MI or stroke). A subject is simultaneously included in the model for time to first event of interest, time to second event of interest, etc., up to the maximum number of events observed for a subject in a study.
In the model for time to Kth event (K=1, 2, etc.), a subject's time starts at randomization and ends at either (1) the time when the subject's Kth event has occurred or (2) the time of death or last follow-up. In the latter case, the subject would be censored. With this approach, we investigated the effect of vorapaxar on the first and each subsequent event as well as the common treatment effect across the entire event history. In addition, we estimated the number needed to treat (NNT) all events as well as the first event. HRs and corresponding CIs are reported. Multivariable analyses were carried out to identify patients who were at risk of having >1 event. Baseline characteristics, randomized treatment, and interactions between the 2 treatment groups were included in the model (Appendices A and B). Factors were selected through forward, backward, and step-wise selection processes. P values were not adjusted for multiple comparisons. Analyses were performed using SAS software (version 9.0; SAS Institute Inc., Cary, NC).
Results
The flow of patients in the TRACER trial and the occurrences of single and recurrent events are shown in Figure 1 . The key secondary composite endpoint of CVD, MI, or stroke occurred in 822 of 6473 patients (12.7%) receiving vorapaxar versus 910 of 6471 patients (14.1%) receiving placebo (HR, 0.89; 95% CI, 0.81 to 0.98; P=0.02) during the follow-up period of 502 days (interquartile range, 349 to 667).
Single Occurrence
As noted in Table 1 and Figure 1 , the number of patients with just 1 occurrence of the composite endpoint of CVD, MI, or 
Multiple Occurrences
As shown in Tables 1 and 2 , patient characteristics associated with increased occurrences of CVD, MI, and stroke events were older age; having diabetes; history of hypertension (HTN), MI, or stroke; peripheral arterial vascular disease; impaired renal function; previous percutaneous coronary intervention and coronary artery bypass grafting; and taking thienopyridine or statins at baseline. Most factors associated with risk for first ischemic event were also associated with recurrent events. As shown in Table 3 , there were more patients with HTN and more current smokers in the placebo group. Multiple recurrent events of CVD, MI, and stroke occurred in 2.6% of patients randomized to vorapaxar and in 2.8% of patients randomized to placebo. Overall, patients randomized to vorapaxar experienced fewer occurrences of events during the study than patients randomized to placebo (HR, 0.88; 95% CI, 0.80 to 0.98; P=0.02; NNT, 51). Recurrent MI occurred in 86 (1.3%) of vorapaxar and 101 (1.6%) placebo patients, whereas recurrent stroke occurred in 4 (<0.1%) vorapaxar and 10 (0.15%) placebo patients. Table 4 shows that there is a nonsignificant effect of vorapaxar on overall occurrences of the expanded composite endpoint (HR, 0.92; 95% CI, 0.84 to 1.01; P=0.09; NNT, 62). Table 5 shows the sequences of events in the order they occurred for patients whose first event was MI or stroke. Figure 2 shows the total number of events for patients whose first events were CVD, MI, or stroke. CVD occurred as a first event in 202 vorapaxar patients (3.1%) and in 208 placebo patients (3.2%). Nonfatal MI or nonfatal stroke occurred before CVD in 170 patients (1.3%), with 90 (1.4%) in the vorapaxar group, and 80 (1.2%) in the placebo group.
Sequence of Events
Recurrence of the expanded endpoint, including revascularization and rehospitalization for recurrent ischemia, occurred in 237 (3.7%) vorapaxar and 449 (6.9%) placebo patients. Figure 3 shows the first and second events with the expanded endpoint. Recurrent revascularization occurred in 14 vorapaxar and 14 placebo patients, and recurrent hospitalization for recurrent ischemia occurred in 4 vorapaxar and 2 placebo patients. Study drug discontinuation was slightly higher in the vorapaxar group, compared to the placebo group (28.2% vs. 26.8%; P=0.07).
Safety
Vorapaxar increased Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) moderate and severe bleeding overall (Table 6 ; HR, 1.42; 95% CI, 1.21 to 1.66; P<0.001). Recurrent GUSTO moderate or severe bleeding occurred in 0.3% of patients, and a second occurrence of Thrombolysis in Myocardial Infarction (TIMI) clinically significant bleeding occurred in 1.7%, a third occurrence in 0.3%, a fourth in 0.04%, and a fifth in 0.02%. Vorapaxar also increased TIMI clinically significant bleeding (1.55; 95% CI, 1.40 to 1.71; P<0.001). Table 7 shows the effect of vorapaxar on overall occurrences of TIMI clinically significant bleeding.
Discussion
In TRACER patients with NSTE ACS, a single component of the key secondary composite endpoint of CVD, MI, or stroke in the time-to-first-event analysis occurred in 10.7% of patients. Multiple recurrent events occurred in 2.7% of patients, meaning that 25.2% of patients included in the time-to-firstevent analysis had recurrent events. Vorapaxar reduced first events by 11% (HR, 0.89; 95% CI, 0.81 to 0.98) and overall ischemic events by 12% (HR, 0.88, 95% CI, 0.80 to 0.98).
The effect of vorapaxar on the reduction of total events was greater than previously reported for time-to-first-event analysis, 2 with the NNT over 502 days reduced from 81 to 51
for the composite endpoint of CVD, MI, or stroke. These data show the importance of capturing recurrent events to ascertain overall patient benefit. Vorapaxar increased moderate and severe bleeding overall as well as recurrent GUSTO moderate and severe bleeding and TIMI clinically significant bleeding. However, recurrent bleeding was infrequent, with 0.4% of patients receiving vorapaxar having a recurrent GUSTO moderate-to-severe bleed and 2.9% having a recurrent TIMI clinically significant bleed, despite continuing therapy in most patients. Among patients who had GUSTO moderate or severe bleeding, 62% of them (60% of vorapaxar and 67% of placebo) never discontinued treatment. Among patients who had TIMI clinically significant bleeding, 69% (67% vorapaxar and 73% placebo) never discontinued treatment. As a reference, among those who never had a bleeding event, 74% (73% vorapaxar and 74% placebo) never discontinued treatment.
These findings increase our understanding of the overall benefit of vorapaxar in addition to treatment with aspirin in patients with NSTE ACS. Clearly, reducing recurrent events is of major clinical benefit. In addition, reducing the total burden of ischemic events may also reduce costs, [5] [6] [7] [8] but must be balanced with the increased bleeding.
Combination and Sequence of Events
With a composite endpoint of CVD, MI, or stroke, there are 7 possible sequences of events if only 1 event of each type occurs. If multiple MI or stroke events occur, there are many more possibilities, as shown in Table 5 . Patients had up to 7 recurrences of MI and 3 had recurrence of 2 strokes. There was a high dependence of recurrent events, with nonfatal MI or nonfatal stroke occurring before CVD in 1.3% of patients. This stresses the importance of continuing vorapaxar and other therapies when a patient experiences nonfatal events.
Factors associated with increased occurrence of events included most risk factors for ischemic events. Taking a thienopyridine or a statin at enrollment was associated with increased occurrence of events. Other studies with P2Y12 inhibitors have shown the efficacy of prasugrel and ticagrelor in reducing recurrent events, as compared with clopidogrel treatment. 6, 9 In the PLATelet inhibition and patient Outcomes was on the primary composite endpoint of CVD, MI, or stroke.
In the current analysis, the effect of vorapaxar on recurrent events was also mostly on first events (1732 of 2080 first events=83.3%).
Limitations
The WLW survival analysis we used for assessment of recurrent events is well validated, 10,11 but the statistical model has a number of limitations, including that the evaluation of treatment effect on recurrent events includes the treatment effect on first events and does not preserve the initial randomization. Recurrent event analyses are also affected by different mortality rates and other postrandomization factors in the 2 randomized treatment groups. Only the former was accounted for by the WLW method. We did not collect information about the size of the recurrent MIs or the disability associated with recurrent strokes. In this analysis, each of the components of the composite endpoint (CVD, MI, or stroke) was weighted equally. However, the relative importance of the components of the composite may differ between clinical trialists, 12 physicians, and patients, and more research is required in this area.
Conclusions
Randomization to vorapaxar nominally reduced the time to first composite event of CVD, MI, or stroke and the risk of recurrent ischemic events. The NNT was reduced from 81 for first events to 51 for recurrent events. Overall recurrent moderate and severe GUSTO bleeding as well as recurrent clinically significant TIMI bleeding was increased with vorapaxar. These exploratory findings increase our knowledge of the overall potential of vorapaxar to reduce ischemic events and of its safety. Focusing only on time-to-first-event analysis may miss important information about efficacy and risks of a therapy. 
